Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases
Background: Cardiometabolic morbidity and medications, specifically Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), have been linked with adverse outcomes from coronavirus disease 2019 (COVID-19). This study aims to investigate, factors associated with COVID-19 positivity in hospital for 1,436 UK Biobank participants; compared with individuals who tested negative, and with the untested, presumed negative, rest of the cohort.
Methods: We studied 7,099 participants from the UK Biobank who had been tested for COVID-19 in hospital. We considered the following exposures: age, sex, ethnicity, body mass index (BMI), diabetes, hypertension, hypercholesterolaemia, ACEi/ARB use, prior myocardial infarction (MI), and smoking. We undertook comparisons between (1) COVID-19 positive and COVID-19 negative tested participants; and (2) COVID-19 tested positive and the remaining participants (tested negative plus untested, n = 494,838). Logistic regression models were used to investigate univariate and mutually adjusted associations.
Results: Among participants tested for COVID-19, Black, Asian, and Minority ethnic (BAME) ethnicity, male sex, and higher BMI were independently associated with a positive result. BAME ethnicity, male sex, greater BMI, diabetes, hypertension, and smoking were independently associated with COVID-19 positivity compared to the remaining cohort (test negatives plus untested). However, similar associations were observed when comparing those who tested negative for COVID-19 with the untested cohort; suggesting that these factors associate with general hospitalization rather than specifically with COVID-19.
Conclusions: Among participants tested for COVID-19 with presumed moderate to severe symptoms in a hospital setting, BAME ethnicity, male sex, and higher BMI are associated with a positive result. Other cardiometabolic morbidities confer increased risk of hospitalization, without specificity for COVID-19. ACE/ARB use did not associate with COVID-19 status.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1007/s00134-020-05991-x
- https://doi.org//10.1001/jamacardio.2020.0950
- https://doi.org//10.1001/jamacardio.2020.1017
- https://doi.org//10.1056/NEJMsr2005760
- https://doi.org//10.1056/NEJMoa2007621
- https://doi.org//10.1001/jamacardio.2020.1624
- https://doi.org//10.1099/mgen.0.000397
- https://doi.org//10.1001/jama.2020.1585
- https://doi.org//10.1016/S0140-6736(20)30183-5
- https://doi.org//10.1017/S0950268815000576
- https://doi.org//10.1016/j.socscimed.2008.12.036
- https://doi.org//10.1016/j.jacc.2012.12.046
- https://doi.org//10.1016/S0140-6736(20)30922-3
- https://doi.org//10.1093/pubmed/fdaa095